Japanese researchers profiled individual T cells from 28 people spanning their 70s to beyond 110, and found that a rare and unusual immune cell, the CD4 cytotoxic T lymphocyte (CD4 CTL), becomes dramatically more common right around the age of 100. These cells are helper T cells that have retrained themselves as killers. In supercentenarians they made up a median of 17.6 percent of all T cells, against 4.0 percent in the 70s-to-90s group. They are dominated by enormous single clones, averaging a third of the entire CD4 CTL pool in one person, which implies decades of repeated stimulation by the same handful of persistent targets. Critically, these cells showed no molecular signs of exhaustion, and the receptor sequences of the biggest clones matched sequences previously catalogued in lung cancer tumors. The authors propose that CD4 CTL expansion is an adaptive rewiring of the aged immune system toward a small set of stubborn antigens, possibly including precancerous and senescent cells.
The oldest people on Earth are not simply people who avoided disease. Their immune systems appear to have reorganized themselves into something structurally different, and a new study puts a number on how different.
Working with blood from 28 Japanese donors, including ten supercentenarians aged over 110, a team from the University of Osaka, RIKEN and Keio University sequenced the transcriptome, the surface proteins and the antigen receptor of 43,584 individual T cells. They were following up their own earlier discovery that supercentenarians carry unusual numbers of CD4 cytotoxic T lymphocytes.
Textbook immunology divides T cells cleanly. CD4 cells are helpers, coordinating the response. CD8 cells are killers, destroying infected and malignant cells. CD4 CTLs break that rule. They are helper-lineage cells that have acquired the killing machinery, and in most adults they are a rounding error, under 5 percent of T cells.
The new data show these cells climbing steadily with age, then rising sharply somewhere around the century mark. The team also built a machine learning classifier and applied it to more than five million cells from 1,512 published samples covering ages 0 to 110-plus, which reproduced the same late-life inflection.
The more revealing finding is what the cells’ receptors look like. In each supercentenarian, the CD4 CTL pool was not a diverse army. It was a few gigantic clones, one of them accounting for 54 percent of that person’s entire CD4 CTL population. Clones that large do not arise by accident. They are the signature of an antigen that keeps showing up, year after year, for decades.
Yet the cells did not look worn out. Exhaustion markers such as PD-1, TIGIT and LAG3 stayed low. And when the researchers searched the receptor sequences against a database of 690 million sequences from nearly 20,000 people, the top clones matched sequences found in tumors, most often non-small-cell lung cancer, even though none of these centenarians had any cancer history.
The authors’ interpretation, offered cautiously, is that living past 100 involves a deliberate narrowing of immune attention. Broad surveillance gives way to a standing garrison aimed at a few persistent threats: latent viruses, senescent cells, and possibly the earliest precancerous lesions that never got to become tumors. That is a story worth telling. It is not yet a proven one.
Insights
There is no intervention in this paper. Read it as a description of what extreme longevity looks like from the inside, not as instructions.
What can honestly be extracted:
The magnitude is real but modest in statistical terms. Median CD4 CTL share was 4.0 percent in the 70s-to-90s group, 9.6 percent in centenarians, 17.6 percent in supercentenarians. That is a 4.4-fold difference between the youngest and oldest groups, or 13.6 percentage points in absolute terms. Converting the reported trend statistic into a standardized effect size gives roughly Cohen’s d of 0.9, conventionally called a large effect. But with only 28 people total, and eight in the youngest group, that estimate carries wide uncertainty and is very likely inflated. Individual variation was enormous: one healthy 100-year-old assigned to the youngest comparison group had the highest CD4 CTL fraction of anyone in the study.
If a highly differentiated, clonally expanded, cytotoxic T cell population is a feature of the healthiest extreme survivors, then longevity strategies built on broadly damping immune activation deserve more scrutiny than they usually get. Not every inflammatory-looking immune signature in an old person is damage. Some of it may be the surveillance that kept them alive.
There is currently no clinical test for CD4 CTL fraction, and no evidence that raising it would help anyone. [Confidence: High]
Context and Source
- Open Access Paper: CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging
- Authors: Hashimoto K, Kojima-Ishiyama M, Inokuchi H, Tagami M, Sasaki T, Mizuguchi K, Okazaki Y, Taniuchi I, Ishigaki K, Hirose N, Carninci P, Arai Y
- Institutions: Institute for Protein Research, The University of Osaka; RIKEN Center for Integrative Medical Sciences, Yokohama; Keio University School of Medicine, Tokyo (Department of Microbiology and Immunology, and Centre for Supercentenarian Medical Research); Human Technopole, Milan, Italy.
- Countries: Japan (primary), with an Italian collaborating institution.
- Journal: Cell Reports (Cell Press / Elsevier). Article 117728, 2026.
- Impact evaluation: The impact score of this journal is 7.7 (most recent Journal Impact Factor; the journal has drifted down from a 2021 peak near 10.0), evaluated against a typical high-end range of 0 to 60-plus for top general science journals, therefore this is a Medium impact journal.